Treatment of hemophilia with fitusiran
US-2024027478-A1 · Jan 25, 2024 · US
Methodologies and reagents for detecting fibrinolysis and hyperfibrinolysis
US10935559B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10935559-B2 |
| Application number | US-201615149868-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 9, 2016 |
| Priority date | May 5, 2014 |
| Publication date | Mar 2, 2021 |
| Grant date | Mar 2, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In some embodiments, the invention provides a container adapted for detecting hyperfibrinolysis or fibrinolysis in a blood sample using viscoelastic analysis comprising an interior having a coating comprises an inhibitor of fibrinolysis.
First claim
Opening claim text (preview).
What is claimed is: 1. A container adapted for detecting hyperfibrinolysis or fibrinolysis in a blood sample using viscoelastic analysis comprising an interior having a coating comprising an inhibitor of fibrinolysis and an inhibitor of platelet function, Wherein the coating is produced by applying a solution comprising both the inhibitor of fibrinolysis and the inhibitor of platelet function to the interior of the container and drying the solution such that it forms the coating on the interior of the container. 2. The container of claim 1 , wherein the inhibitor of fibrinolysis is tranexamic acid. 3. The container of claim 1 , wherein the inhibitor of fibrinolysis is selected from the group consisting of aminocaproic acid, ε-aminocaproic acid, and aprotinin. 4. The container of claim 1 , wherein the viscoelastic analysis is performed using a thromboelastography analyzer system or in a thromboelastometry analyzer system. 5. The container of claim 1 , wherein the inhibitor of fibrinolysis is formulated with sugar in the coating. 6. The container of claim 1 , wherein the inhibitor is formulated with sodium azide in the coating. 7. The container of claim 1 , wherein the inhibitor of platelet function is a glycoprotein IIb/IIIa receptor inhibitor. 8. The container of claim 7 , wherein the glycoprotein IIb/IIIa receptor inhibitor is selected from the group consisting of abciximab, eptifibatide, and tirofiban. 9. The container of claim 1 , wherein the inhibitor of platelet function is an adenosine diphosphate (ADP) receptor inhibitor, adenosine reuptake inhibitor, or a thromboxane inhibitor. 10. The container of claim 1 , wherein the inhibitor of platelet function is cytochalasin D. 11. The container of claim 1 , wherein the container is located on a cassette, wherein the cassette further comprises a second container.
Assignees
Inventors
Classifications
involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen · CPC title
Blood {(chemical methods for determining blood cell populations G01N33/5094; chemical analysis of blood groups or blood types G01N33/80)} · CPC title
- G01N33/86Primary
involving blood coagulating time {or factors, or their receptors} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10935559B2 cover?
- In some embodiments, the invention provides a container adapted for detecting hyperfibrinolysis or fibrinolysis in a blood sample using viscoelastic analysis comprising an interior having a coating comprises an inhibitor of fibrinolysis.
- Who is the assignee on this patent?
- Haemonetics Corp, Univ Colorado Regents
- What technology area does this patent fall under?
- Primary CPC classification G01N33/86. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).